Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review.
Kanabar, Shivani Setur Tiwari, Abhinav Soran, Vina Balendran, Prashanthan Price, Malcolm Turner, Alice Margaret
Kanabar, Shivani Setur
Tiwari, Abhinav
Soran, Vina
Balendran, Prashanthan
Price, Malcolm
Turner, Alice Margaret
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-06-10
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Despite comprising many cancer diagnoses, few treatments are suitable for patients with advanced non-small cell lung cancer (aNSCLC). Trials suggest blockade of programmed death 1 (PD1) or its ligand (PDL1) may be effective for these patients. However, this therapy's impact on outcomes other than survival, and outcomes of patients not in trials, remains largely unknown. Therefore, we compared the effectiveness of PD1 and PDL1 immunotherapy to chemotherapy and placebo across multiple clinical outcomes.
Methods: Six databases were searched on 12-13 October 2019 for randomised controlled trials (RCTs) and observational studies investigating nivolumab, pembrolizumab, atezolizumab or durvalumab. Study selection was performed independently by two reviewers. Data for overall survival, progression-free survival, adverse effects (AEs) and quality of life (QoL) were descriptively and meta-analysed. Factors impacting treatment outcomes, including PDL1 expression, were explored. The similarity between RCT and observational data was assessed.
Results: From 5423 search results, 139 full texts and abstracts were included. Immunotherapy was associated with a lower risk of death than both comparators. In RCTs, the incidence of treatment-related AEs was approximately 20% lower among patients using immunotherapy compared with chemotherapy. However, no other consistent benefits were observed. Progression-free survival results were inconsistent. Improvements to QoL varied according to the instrument used; however, QoL was not recorded widely. Survival results were similar between study designs; however, AEs incidence was lower in observational studies.
Discussion: Among patients with aNSCLC, immunotherapy improved overall survival and incidence of treatment-related AEs compared with chemotherapy. Benefits to progression-free survival and QoL were less consistent.
Citation
Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax. 2022 Dec;77(12):1163-1174. doi: 10.1136/thoraxjnl-2020-215614. Epub 2022 Jun 10
Type
Article